NE vs NOV
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Noble Corporation exhibits a paradoxical profile: a perfect Piotroski F-Score of 9/9 indicates exceptional short-term financial health and balance sheet strength, yet the stock is fundamentally overvalued. Trading at $51.03, it sits significantly above its Graham Number ($30.35) and Intrinsic Value ($35.54). This valuation premium is unsupported by negative revenue growth and a highly unsustainable dividend payout ratio of 139.86%. While the balance sheet is pristine, bearish insider activity from the CEO and CFO, combined with a poor earnings surprise track record, suggests limited upside at current levels.
NOV exhibits a stark divergence between operational health and financial performance. While the Piotroski F-Score of 8/9 indicates strong underlying balance sheet health and liquidity, the company is struggling with razor-thin profit margins (1.05%) and a catastrophic dividend payout ratio of 210%. The stock is trading at a significant premium to its Graham Number ($9.89) and Intrinsic Value ($1.75), suggesting the market is pricing in a recovery that is not yet reflected in the negative YoY revenue and earnings growth. Overall, the strong solvency provides a safety net, but the lack of earnings beats and bearish technicals limit upside potential.
Compare Another Pair
NE vs NOV: Head-to-Head Comparison
This page compares Noble Corporation plc (NE) and NOV Inc. (NOV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.